{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:34:41Z","timestamp":1790231681299,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,9,13]],"date-time":"2016-09-13T00:00:00Z","timestamp":1473724800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sanofi and Regeneron Pharmaceuticals Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s10557-016-6685-y","type":"journal-article","created":{"date-parts":[[2016,9,13]],"date-time":"2016-09-13T02:12:01Z","timestamp":1473732721000},"page":"473-483","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":187,"title":["Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160\u00a0mg\/dl or Higher"],"prefix":"10.1007","volume":"30","author":[{"given":"Henry N.","family":"Ginsberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Rader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick J.","family":"Raal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Guyton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie T.","family":"Baccara-Dinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Lorenzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Pordy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stroes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,13]]},"reference":[{"key":"6685_CR1","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European atherosclerosis society. Eur Heart J. 2013;34:3478\u20133390a.","journal-title":"Eur Heart J"},{"key":"6685_CR2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2014.10.002","volume":"8","author":"HE Bays","year":"2014","unstructured":"Bays HE, Jones PH, Brown WV, et al. National Lipid Association Annual Summary of clinical Lipidology 2015. J Clin Lipidol. 2014;8:S1\u2013S36.","journal-title":"J Clin Lipidol"},{"key":"6685_CR3","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0002-9149(00)01429-6","volume":"87","author":"PN Hopkins","year":"2001","unstructured":"Hopkins PN, Stephenson S, LL W, et al. Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia. Am J Cardiol. 2001;87:547\u201353.","journal-title":"Am J Cardiol"},{"key":"6685_CR4","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"Z Reiner","year":"2011","unstructured":"Reiner Z, Catapano AL, De BG, et al. ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European atherosclerosis society (EAS). Eur Heart J. 2011;32:1769\u2013818.","journal-title":"Eur Heart J"},{"key":"6685_CR5","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387\u201397.","journal-title":"N Engl J Med"},{"key":"6685_CR6","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1093\/eurheartj\/ehn422","volume":"29","author":"A Neil","year":"2008","unstructured":"Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J. 2008;29:2625\u201333.","journal-title":"Eur Heart J"},{"key":"6685_CR7","doi-asserted-by":"crossref","first-page":"e9220","DOI":"10.1371\/journal.pone.0009220","volume":"5","author":"R Huijgen","year":"2010","unstructured":"Huijgen R, Kindt I, Verhoeven SB, et al. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS One. 2010;5:e9220.","journal-title":"PLoS One"},{"key":"6685_CR8","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.atherosclerosis.2014.02.021","volume":"234","author":"S Beliard","year":"2014","unstructured":"Beliard S, Carreau V, Carrie A, et al. Improvement in LDL-cholesterol levels of patients with familial hypercholesterolemia: can we do better? Analysis of results obtained during the past two decades in 1669 French subjects. Atherosclerosis. 2014;234:136\u201341.","journal-title":"Atherosclerosis"},{"key":"6685_CR9","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","volume":"114","author":"NG Seidah","year":"2014","unstructured":"Seidah NG, Awan Z, Chretien M, et al. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014;114:1022\u201336.","journal-title":"Circ Res"},{"key":"6685_CR10","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10557-014-6523-z","volume":"28","author":"JJ Kastelein","year":"2014","unstructured":"Kastelein JJ, Robinson JG, Farnier M, et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies. Cardiovasc Drugs Ther. 2014;28:281\u20139.","journal-title":"Cardiovasc Drugs Ther"},{"key":"6685_CR11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"EA Stein","year":"2012","unstructured":"Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727\/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380:29\u201336.","journal-title":"Lancet"},{"key":"6685_CR12","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"F Raal","year":"2012","unstructured":"Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012;126:2408\u201317.","journal-title":"Circulation"},{"key":"6685_CR13","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","volume":"385","author":"FJ Raal","year":"2014","unstructured":"Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2014;385:331\u201340.","journal-title":"Lancet"},{"key":"6685_CR14","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","volume":"366","author":"EA Stein","year":"2012","unstructured":"Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366:1108\u201318.","journal-title":"N Engl J Med"},{"key":"6685_CR15","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.jacc.2012.08.986","volume":"60","author":"CS Dias","year":"2012","unstructured":"Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol. 2012;60:1888\u201398.","journal-title":"J Am Coll Cardiol"},{"key":"6685_CR16","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","volume":"59","author":"JM McKenney","year":"2012","unstructured":"McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59:2344\u201353.","journal-title":"J Am Coll Cardiol"},{"key":"6685_CR17","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","volume":"9","author":"PM Moriarty","year":"2015","unstructured":"Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9:758\u201369.","journal-title":"J Clin Lipidol."},{"key":"6685_CR18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2015.11.010","volume":"244","author":"M Farnier","year":"2016","unstructured":"Farnier M, Jones P, Severance R, et al. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial. Atherosclerosis. 2016;244:138\u201346.","journal-title":"Atherosclerosis"},{"key":"6685_CR19","doi-asserted-by":"crossref","unstructured":"Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78\u00a0week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36:2996\u20133003.","DOI":"10.1093\/eurheartj\/ehv370"},{"key":"6685_CR20","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1210\/jc.2015-1520","volume":"100","author":"H Bays","year":"2015","unstructured":"Bays H, Gaudet D, Weiss R, et al. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial. J Clin Endocrinol Metab. 2015;100:3140\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"6685_CR21","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","volume":"36","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36:1186\u201394.","journal-title":"Eur Heart J"},{"key":"6685_CR22","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","volume":"367","author":"EM Roth","year":"2012","unstructured":"Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367:1891\u2013900.","journal-title":"N Engl J Med"},{"key":"6685_CR23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","volume":"176","author":"EM Roth","year":"2014","unstructured":"Roth EM, Taskinen MR, Ginsberg HN, et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24\u00a0week, double-blind, randomized phase 3 trial. Int J Cardiol. 2014;176:55\u201361.","journal-title":"Int J Cardiol"},{"key":"6685_CR24","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","volume":"169","author":"DJ Kereiakes","year":"2015","unstructured":"Kereiakes DJ, Robinson JG, Cannon CP, et al. Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart J. 2015;169:906\u201315.","journal-title":"Am Heart J"},{"key":"6685_CR25","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489\u201399.","journal-title":"N Engl J Med"},{"key":"6685_CR26","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/bmj.303.6807.893","volume":"303","author":"Risk of fatal coronary heart disease in familial hypercholesterolaemia","year":"1991","unstructured":"Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific steering committee on behalf of the Simon Broome register group. BMJ. 1991;303:893\u20136.","journal-title":"BMJ"},{"key":"6685_CR27","unstructured":"World Health Organization: Familial Hypercholesterolemia (FH). 1998; Available at: http:\/\/whqlibdoc.who.int\/hq\/1999\/WHO_HGN_FH_CONS_99.2.pdf?ua=1 . Accessed 18 Aug 2016."},{"key":"6685_CR28","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499\u2013502.","journal-title":"Clin Chem"},{"key":"6685_CR29","doi-asserted-by":"crossref","unstructured":"Siddiqui O, Hung HM, O\u2019Neill R MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat 2009; 19:227\u2013246.","DOI":"10.1080\/10543400802609797"},{"key":"6685_CR30","unstructured":"Trials NRCUPoHMDiC:(2010) The prevention and treatment of missing data in clinical trials. National Academies Press (US): Washington (DC)"},{"key":"6685_CR31","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/j.1541-0420.2012.01780.x","volume":"68","author":"DV Mehrotra","year":"2012","unstructured":"Mehrotra DV, Li X, Liu J, et al. Analysis of longitudinal clinical trials with missing data using multiple imputation in conjunction with robust regression. Biometrics. 2012;68:1250\u20139.","journal-title":"Biometrics"},{"key":"6685_CR32","first-page":"B95","volume":"34","author":"GR Cooper","year":"1988","unstructured":"Cooper GR, Myers GL, Smith SJ, et al. Standardization of lipid, lipoprotein, and apolipoprotein measurements. Clin Chem. 1988;34:B95\u2013105.","journal-title":"Clin Chem"},{"key":"6685_CR33","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","volume":"308","author":"D Sullivan","year":"2012","unstructured":"Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012;308:2497\u2013506.","journal-title":"JAMA"},{"key":"6685_CR34","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","volume":"63","author":"E Stroes","year":"2014","unstructured":"Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63:2541\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"6685_CR35","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","volume":"315","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of Evolocumab vs Ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315:1580\u201390.","journal-title":"JAMA"},{"key":"6685_CR36","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cjca.2012.11.032","volume":"29","author":"TJ Anderson","year":"2013","unstructured":"Anderson TJ, Gregoire J, Hegele RA, et al. 2012 update of the Canadian cardiovascular society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;29:151\u201367.","journal-title":"Can J Cardiol"},{"key":"6685_CR37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.5551\/jat.14.45","volume":"14","author":"T Teramoto","year":"2007","unstructured":"Teramoto T, Sasaki J, Ueshima H, et al. Executive summary of Japan atherosclerosis society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb. 2007;14:45\u201350.","journal-title":"J Atheroscler Thromb"},{"key":"6685_CR38","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2011.04.003","volume":"5","author":"AC Goldberg","year":"2011","unstructured":"Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5:S1\u20138.","journal-title":"J Clin Lipidol"},{"key":"6685_CR39","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","volume":"168","author":"GG Schwartz","year":"2014","unstructured":"Schwartz GG, Bessac L, Berdan LG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014;168:682\u20139.","journal-title":"Am Heart J"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-016-6685-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-016-6685-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-016-6685-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T23:55:57Z","timestamp":1601078157000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-016-6685-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,13]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["6685"],"URL":"https:\/\/doi.org\/10.1007\/s10557-016-6685-y","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,13]]}}}